Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of zilovertamab vedotin alone or with nemtabrutinib in relapsed/refractory B-cell malignancies
MOH_2022-04-11_010707Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of zilovertamab vedotin and nemtabrutinib in B-cell malignancy, mantle cell lymphoma (MCL), Richter's syndrome (RS) and 2 more (8 cohorts), sponsored by Merck & Co. Started Apr 2022; status: active, not recruiting.
02
Drugs
zilovertamab vedotinnemtabrutinib
03
Conditions
B-cell malignancymantle cell lymphoma (MCL)Richter's syndrome (RS)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2022-04-11_010707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-11_010707.